Upadacitinib - 99%, high purity , CAS No.1310726-60-3, Inhibitor of Janus kinase 1;Inhibitor of Janus kinase 2;Inhibitor of Janus kinase 3;Inhibitor of tyrosine kinase 2
Upadacitinib - 99%, high purity , CAS No.1310726-60-3, Inhibitor of Janus kinase 1;Inhibitor of Janus kinase 2;Inhibitor of Janus kinase 3;Inhibitor of tyrosine kinase 2
1.Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyland D et al.. (2018) In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).. BMC Rheumatol, 2 (3):(23). [PMID:30886973]
2.Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR et al.. (2019) Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.. Front Pharmacol, 10 (3):(212). [PMID:30930775]
3.Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA et al.. (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.. Lancet, 393 (10188):(2303-2311). [PMID:31130260]
4.Torgutalp M, Poddubnyy D. (2018) Emerging treatment options for spondyloarthritis.. Best Pract Res Clin Rheumatol, 32 (3):(472-484). [PMID:31171316]
5.Mohamed MF, Klünder B, Camp HS, Othman AA. (2019) Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.. Clin Pharmacol Ther, 106 (6):(1319-1327). [PMID:31194885]
6.Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y et al.. (2019) Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.. Arthritis Rheumatol, 71 (11):(1788-1800). [PMID:31287230]
D2426083